Trial Profile

A Phase II Study of MK-2206 for Recurrent Malignant Glioma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 13 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 2206 (Primary)
Indications Glioblastoma; Gliosarcoma
Focus Biomarker; Pharmacodynamics; Therapeutic Use

Most Recent Events

06 Apr 2011 Status changed from not yet recruiting to withdrawn prior to recruitment, due to Merck undergoing reprioritization of clinical trials, and terminating many in oncology including this one, according to ClinicalTrials.gov.
07 Dec 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com